Enhancing Oncology Model (EOM) Fact Sheet
Download to see features of the new healthcare delivery model and value-based care payment system for oncology practices, administered by the Centers for Medicare and Medicaid Services (CMS).
Enhancing Oncology Model (EOM) White Paper: Perspectives from Oncology Practices and the Path Forward in Value-Based Care
To gather early perceptions of the EOM and understand how oncology practices evaluated participation decisions in the new model, Magnolia facilitated an advisory panel discussion with key opinion leaders.
Developing strategic game plans in response to shifts in federal policy
Biopharmaceutical companies engaged Magnolia to help them understand the implications of the Inflation Reduction Act of 2022 and develop long-term strategic plans to adjust for the sweeping market changes it will cause.
Launch planning in an ever-evolving policy and regulatory landscape
A development-stage biopharma company engaged Magnolia to help understand the impact that the IRA would have on their product development strategies.
Developing the appropriate regulatory strategy for a patient-centric, therapy-agnostic app
A biopharma company engaged Magnolia to assess both the regulatory process as well as the likelihood of uptake of a therapy-agnostic phone app to support the patient journey for a rare pulmonary disease.
Using payer and age mix as the basis for developing a go-to-market strategy for a prelaunch drug
A biopharma company prepping to launch a biosimilar needed to know payer segments and patient age demographics.
Designing a coding gameplan for a soon-to-launch infused biologic
A biopharma company needed an inpatient coding analysis for their new medication.
Lining up support for a New Technology Add-on Payment in a rare-disease treatment
A biopharma company wanted to know the likelihood of receiving an NTAP after launching an inpatient treatment.
Using published evidence and compendia to support expanded coverage for an off-label medication dosage
A pharma company needed to evaluate the likelihood that drug compendia would positively rate an off-label dosage of an FDA-approved medication to support additional payer coverage.
Pricing an oral formulation for a bioequivalent COPD product
A biopharma company needed an appropriate pricing model for a new tablet formulation of a successful existing infusion.